Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Class A Common Stock, Par Value $.0001
-
Shares outstanding
-
98,437,808
-
Total 13F shares
-
44,799,019
-
Share change
-
+34,730,267
-
Total reported value
-
$60,478,537
-
Put/Call ratio
-
6.4%
-
Price per share
-
$1.35
-
Number of holders
-
61
-
Value change
-
+$47,505,485
-
Number of buys
-
47
-
Number of sells
-
8
Institutional Holders of Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI) as of Q4 2025
As of 31 Dec 2025,
Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,799,019 shares.
The largest 10 holders included
SAMSARA BIOCAPITAL, LLC, RA CAPITAL MANAGEMENT, L.P., AWM Investment Company, Inc., SymBiosis Capital Partners, LLC, VANGUARD GROUP INC, Longaeva Partners L.P., Siren, L.L.C., GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., and Nan Fung Group Holdings Ltd.
This page lists
61
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.